264 related articles for article (PubMed ID: 16720199)
41. The role of alemtuzumab in the management of T-cell malignancies.
Dearden C
Semin Oncol; 2006 Apr; 33(2 Suppl 5):S44-52. PubMed ID: 16720203
[TBL] [Abstract][Full Text] [Related]
42. What choices are available for treatment of the patient with chronic lymphocytic leukemia who is fludarabine-refractory?
Byrd JC; Rai KR
Semin Oncol; 2000 Aug; 27(4):xii-xv; discussion xv-xvi. PubMed ID: 10950363
[No Abstract] [Full Text] [Related]
43. Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial.
Elter T; Borchmann P; Schulz H; Reiser M; Trelle S; Schnell R; Jensen M; Staib P; Schinköthe T; Stützer H; Rech J; Gramatzki M; Aulitzky W; Hasan I; Josting A; Hallek M; Engert A
J Clin Oncol; 2005 Oct; 23(28):7024-31. PubMed ID: 16145065
[TBL] [Abstract][Full Text] [Related]
44. U.S. Food and Drug Administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab.
Lemery SJ; Zhang J; Rothmann MD; Yang J; Earp J; Zhao H; McDougal A; Pilaro A; Chiang R; Gootenberg JE; Keegan P; Pazdur R
Clin Cancer Res; 2010 Sep; 16(17):4331-8. PubMed ID: 20601446
[TBL] [Abstract][Full Text] [Related]
45. Alemtuzumab as first-line therapy for B-cell chronic lymphocytic leukemia: long-term follow-up of clinical effects, infectious complications and risk of Richter transformation.
Karlsson C; Norin S; Kimby E; Sander B; Porwit Macdonald A; Nilsson B; Johansson E; Mellstedt H; Lundin J; Osterborg A
Leukemia; 2006 Dec; 20(12):2204-7. PubMed ID: 17051245
[No Abstract] [Full Text] [Related]
46. Mycobacterium avium complex infection after alemtuzumab therapy for chronic lymphocytic leukemia.
Saadeh CE; Srkalovic G
Pharmacotherapy; 2008 Feb; 28(2):281-4. PubMed ID: 18225973
[TBL] [Abstract][Full Text] [Related]
47. Reconstitution of the T-cell repertoire following treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with B-cell chronic lymphocytic leukaemia.
Rezvany MR; Tehrani MJ; Karlsson C; Lundin J; Rabbani H; Osterborg A; Mellstedt H
Br J Haematol; 2006 Nov; 135(4):475-85. PubMed ID: 16995884
[TBL] [Abstract][Full Text] [Related]
48. Alemtuzumab: a new option for refractory chronic lymphocytic leukemia?
Smith JA
Cancer Pract; 2001; 9(4):211-3. PubMed ID: 11879313
[No Abstract] [Full Text] [Related]
49. Phase II study of alemtuzumab in chronic lymphoproliferative disorders.
Ferrajoli A; O'Brien SM; Cortes JE; Giles FJ; Thomas DA; Faderl S; Kurzrock R; Lerner S; Kontoyiannis DP; Keating MJ
Cancer; 2003 Aug; 98(4):773-8. PubMed ID: 12910522
[TBL] [Abstract][Full Text] [Related]
50. Treatment of fludarabine-refractory chronic lymphocytic leukemia.
Tsimberidou AM; Keating MJ
Cancer; 2009 Jul; 115(13):2824-36. PubMed ID: 19402170
[TBL] [Abstract][Full Text] [Related]
51. Alemtuzumab in the treatment of chronic lymphocytic leukemia.
Robak T
BioDrugs; 2005; 19(1):9-22. PubMed ID: 15691213
[TBL] [Abstract][Full Text] [Related]
52. Treatment of chronic lymphocytic leukemia.
Ferrajoli A; O'Brien SM
Semin Oncol; 2004 Apr; 31(2 Suppl 4):60-5. PubMed ID: 15124136
[TBL] [Abstract][Full Text] [Related]
53. Clinical effects of alemtuzumab (Campath-1H) in B-cell chronic lymphocytic leukemia.
Osterborg A; Mellstedt H; Keating M
Med Oncol; 2002; 19 Suppl():S21-6. PubMed ID: 12180488
[TBL] [Abstract][Full Text] [Related]
54. Future prospects for alemtuzumab (MabCampath).
Rai K; Hallek M
Med Oncol; 2002; 19 Suppl():S57-63. PubMed ID: 12180493
[TBL] [Abstract][Full Text] [Related]
55. Rapid and durable molecular response of refractory T-cell large granular lymphocyte leukemia after alemtuzumab treatment.
Monjanel H; Hourioux C; Arbion F; Colombat P; Lissandre S; Regner MP; Senecal D
Leuk Res; 2010 Aug; 34(8):e197-9. PubMed ID: 20211489
[No Abstract] [Full Text] [Related]
56. The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy.
Tam CS; O'Brien S; Lerner S; Khouri I; Ferrajoli A; Faderl S; Browning M; Tsimberidou AM; Kantarjian H; Wierda WG
Leuk Lymphoma; 2007 Oct; 48(10):1931-9. PubMed ID: 17917961
[TBL] [Abstract][Full Text] [Related]
57. NCCN: New directions in chronic lymphocytic leukemia.
O'Brien S
Cancer Control; 2001; 8(6 Suppl 2):114-7. PubMed ID: 11760553
[No Abstract] [Full Text] [Related]
58. Alemtuzumab in relapsed or refractory chronic lymphocytic leukemia and prolymphocytic leukemia.
McCune SL; Gockerman JP; Moore JO; Decastro CM; Bass AJ; Chao NJ; Long GD; Vredenburgh JJ; Gasparetto C; Adams D; Payne N; Rizzieri DA
Leuk Lymphoma; 2002 May; 43(5):1007-11. PubMed ID: 12148879
[TBL] [Abstract][Full Text] [Related]
59. Progress with alemtuzumab in chronic lymphocytic leukemia: Update from the 2003 meeting of the american society of hematology.
Lee D
Clin Lymphoma; 2004 Mar; 4(4):217-9. PubMed ID: 15072612
[No Abstract] [Full Text] [Related]
60. Signaling molecules and cytokine production in T cells of patients with B-cell chronic lymphocytic leukemia: long-term effects of fludarabine and alemtuzumab treatment.
Kiaii S; Choudhury A; Mozaffari F; Rezvany R; Lundin J; Mellstedt H; Osterborg A
Leuk Lymphoma; 2006 Jul; 47(7):1229-38. PubMed ID: 16923551
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]